Switzerland · Delayed Price · Currency is CHF Idorsia Earnings Call Transcripts
Fiscal Year 2026
-
A phase II study in children with insomnia, including those with neurodevelopmental disorders, showed daridorexant significantly increased sleep time and improved morning alertness with a strong safety profile. The results suggest potential benefits beyond insomnia and support further regulatory discussions for pediatric and NDD indications.
-
Restructured debt and strong commercial execution have positioned the company for growth, with Quviviq outperforming sales expectations and expanding globally. The pipeline advances with pivotal trials for lucerastat and new programs in dermatology and neurology, while partnership strategies aim to maximize asset value.
-
Leadership outlined a focused strategy to commercialize two key assets, Quviviq and Tryvio, while advancing a robust pipeline and global expansion. Quviviq targets both nighttime and daytime insomnia symptoms, with pediatric trials and U.S. relaunch planned. Tryvio addresses resistant hypertension with strong efficacy and broad adoption potential.
Fiscal Year 2025
-
2025 saw a turnaround with QUVIVIQ sales more than doubling and operating losses sharply reduced, driven by commercial execution and cost control. TRYVIO/JERAYGO gained regulatory traction, and the pipeline advanced with clear plans for Fabry disease and immunology assets.
-
The company is expanding its European presence and expects to double QUVIVIQ revenues in 2025, while awaiting a US descheduling decision that could broaden access. Key pipeline assets are advancing, including a phase 1 orexin agonist and late-stage partnered programs, with several clinical milestones expected through 2026.
-
TriVia, a first-in-class endothelin pathway inhibitor, addresses a major unmet need in resistant hypertension, showing strong efficacy and safety in high-risk groups. With broad FDA labeling, robust market opportunity, and positive physician and payer feedback, commercial launch and partnering efforts are advancing.
-
Net revenue more than doubled year-over-year, driven by QUVIVIQ's strong growth in Europe and Canada, with operational turnaround reflected in a sharply reduced non-GAAP loss. Guidance remains unchanged, with commercial profitability targeted for 2026 and overall profitability by end-2027.
-
Secured bondholder support and new funding, significantly extending the cash runway and reducing debt. Convertible bond restructuring involves an SPV, with asset rights returning after debt repayment. Key priorities are finding a partner for aprocitentan and driving QUVIVIQ's growth.
-
Key operational priorities include securing an aprocitentan deal, restructuring, and funding to extend cash runway. QUVIVIQ drives growth with stable sales, expanding reimbursement, and new partnerships, while a focused pipeline and cost reductions aim for mid-term profitability.
Fiscal Year 2024
-
Strong QUVIVIQ sales growth in EUCAN and stable U.S. performance, combined with major financial restructuring and new funding, have secured operations into 2026. Tryvio launched in the U.S. and EU, with ongoing efforts to unlock further value through partnerships and regulatory changes.
-
Revenue doubled year-over-year, driven by QUVIVIQ sales growth and cost reductions. Cash position strengthened by the Viatris deal, with a focus on launching TRYVIO and securing an aprocitentan partnership to extend the cash runway.